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Prematurity is a major public health problem in the United States and worldwide. Women
with a history of a previous preterm birth are at high risk for recurrence. Progesterone is a
key hormone involved in pregnancy maintenance. In general, progesterone is thought to
maintain pregnancy through several closely linked mechanisms: (1) promotion of uterine
quiescence, (2) inhibition of pro-inflammatory cells, and (3) immunosuppressive action. 17-
Alpha hydroxyprogesterone caproate is currently the only medication approved to prevent
recurrent preterm birth. The purpose of this review is to discuss the history of 17-alpha
hydroxyprogesterone caproate use for recurrent preterm birth prevention, the rationale
behind 17-alpha hydroxyprogesterone caproate administration, and current evidence-
based indications for 17-alpha hydroxyprogesterone caproate use.Introduction
Preterm delivery (birth prior to 37 weeks' gestation) complicates
approximately 1 in 10 pregnancies in the United States, is the
leading cause of morbidity and mortality among non-anoma-
lous singleton neonates, and remains a major public health
problem worldwide.1–6 Survivors remain at increased risk for
life-long complications, including reduced school performance,
behavioral and cognitive difficulties, and medical problems
affecting nearly all major organ systems.7–9 Over the last several
decades, though significant advances have been made in the
care of the preterm neonate, resulting in lowering the threshold
of viability to 22 weeks' gestation in some tertiary care centers,
similar advances have not been made in obstetrics, and preterm
birth remains difficult to predict, prevent, and treat.
The physiologic processes that occur to initiate term and
preterm labor are complex, multifactorial, and incompletely4 understood. Normal pregnancy maintenance depends on main-
taining uterine quiescence despite both internal and external
stimuli. External stimuli that may lead to aberrations in the
maintenance of pregnancy and thus, preterm delivery, include
factors such as infection (bacterial and viral), decidual hemor-
rhage, uterine stretch due to overdistention, and maternal or
fetal stress.10,11 The contribution of the fetus and the placenta
are also important but often overlooked; the unique fetal
genome and physiologically active placental tissue with the
ability to synthesize steroid hormones may play a pivotal role in
the pathogenesis of preterm birth in some pregnancies. Finally,
hormonal abnormalities may contribute to adverse pregnancy
outcomes and variation in the timing of parturition.10,11
Supplementation with progesterone during pregnancy is
currently the only effective option for the prevention of
spontaneous preterm birth in certain high-risk subgroups.
Unfortunately, even progesterone supplementation is
imperfect, and the mechanisms of action remain poorly
understood. Paramount to determining the success of pro-
gesterone supplementation during pregnancy is identifying
women who will benefit. Regrettably, progesterone is not a
panacea and it is not efficacious for all women and for all
preterm birth indications. Therefore, it is not unexpected that
some recent studies of progesterone in pregnancy have
reported negative findings.
The purpose of this review is to discuss the history of
progesterone use for preterm birth prevention in the United
States, and to provide a basis for understanding why this
therapy has been widely studied yet has been met with
disparate results. We will discuss possible mechanisms of
action of progesterone in general and describe current evi-
dence-based indications for progesterone for the prevention
of spontaneous preterm birth, focusing on 17-alpha hydrox-
yprogesterone caproate (17-OHPC, trade name Makena,
AMAG Pharmaceuticals, Inc.), currently the only medication
approved by the Food and Drug Administration (FDA) for the
purposes of prematurity prevention.History of use of 17-OHPC for preterm birth
prevention
Though 17-OHPC was initially approved by the FDA in 1956
(under the trade name Delalutin) for the treatment of
menstrual disorders, uterine cancer, and miscarriage, the
first reports of progesterone supplementation for preterm
birth prevention were published in the 1960s. One of the first
reports included 99 women at high risk for preterm birth
from Paris, France; study participants received either intra-
muscular progesterone three times per week or placebo
between 28 and 32 weeks' gestation, and those receiving
progesterone had a reduced risk of preterm birth (OR ¼ 0.24,
95% CI: 0.07–0.82).12 Unfortunately, inconsistent results, poor
study design including heterogeneous inclusion criteria,
and theoretical concerns regarding safety limited clinical
application of progesterone in the 1960s and 1980s during
pregnancy.
In 1990, a meta-analysis of progesterone use in pregnancy
was published by Keirse et al., concluding that while there
was no support for the role of progesterone in prevention of
miscarriage, it may be effective as a prophylactic agent for
preterm birth (pooled OR ¼ 0.50, 95% CI: 0.30–0.85).12 This new
enthusiasm for the use of progesterone for preterm birth
prevention prompted several trials that were eventually
conducted and reported in the early 2000s. Most notably, in
a large multi-center randomized controlled trial (RCT) con-
ducted by the NICHD Maternal–Fetal Medicine Units Network,
Meis et al randomized 463 women with a history of a prior
spontaneous preterm birth to 250 mg weekly intramuscular
injections of 17-OHPC vs. placebo. The rate of recurrent
spontaneous preterm birth o37 weeks' gestation was
reduced from 55% in the placebo group to 36% in the 17-
OHPC group (RR ¼ 0.66, 95% CI: 0.54–0.81).13 It was primarily
due to the results of this landmark trial that have led to
current day (2017) recommendations for 17-OHPC use in
clinical practice.Rationale for studying progesterone
Progesterone is a key hormone involved in pregnancy main-
tenance. In early pregnancy, the presence of progesterone is
crucial to the survival of the developing embryo. It is
produced by the corpus luteum, and if disrupted, or if an
anti-progestin is administered, the pregnancy is lost.14 By
approximately 10 weeks' gestation, primary production of
progesterone is assumed by the developing placenta, but
the role of progesterone later in pregnancy is less clearly
defined.15 Administration of progesterone antagonists to
women at term will induce cervical ripening and labor; in
mouse models, administration of progesterone antagonists
during the preterm time period results in premature
delivery.16 In sheep, goats, and mice, an absolute decrease
in progesterone levels and an increase in estrogen precede
the onset of labor. In contrast, a relative withdrawal of
progesterone at the level of the receptor is thought to precede
the initiation of labor in humans.16 Though there is consen-
sus that an absolute or relative withdrawal of progesterone is
necessary in most mammals for the initiation of both normal
and abnormal labor, the mechanisms by which this occurs
are incompletely understood.17 In general, progesterone is
thought to maintain pregnancy through several closely linked
mechanisms: (1) promotion of uterine quiescence, (2) inhib-
ition of pro-inflammatory cells, and (3) immunosuppressive
action.
Mechanisms of action
Progesterone exerts its action through several different iso-
forms of the intracellular progesterone receptor, a member of
the steroid-receptor superfamily of nuclear receptors. Proges-
terone Receptor B (PR-B) is the predominant form of the
receptor found during pregnancy in humans. Binding of
progesterone to PR-B induces a conformational change in
the receptor, promoting the transcription of genes that
promote uterine relaxation. In contrast, Progesterone Recep-
tor A (PR-A) is a truncated form of the progesterone receptor,
and lacks the 164 N-terminal residues. PR-A acts as a
repressor of PR-B function. An increase in the ratio of PR-A
to PR-B is associated with the onset of labor in humans,
creating a functional progesterone withdrawal at the level of
the receptor.18,19
Progesterone is also theorized to have anti-inflammatory
activity. Some of these actions are mediated through the
inhibition of monocyte chemoattractant protein-1 (MCP-1), a
chemokine that increases in maternal serum during preterm
and term labor.20 MCP-1 stimulates recruitment of monocytes
to the myometrium. Monocytes serve as precursors to tissue
macrophages, a key element to the inflammatory cascade.20
Immunosuppressive effects of progesterone have been dem-
onstrated in multiple in vitro studies. Inflammation is a
common underlying etiology of preterm birth, and is most
objectively defined histologically, occurring due to the infil-
tration of tissues by neutrophils, macrophages, and
lymphocytes.21
In one study, stimulation of placental cotyledons with an
infectious agent (Escherichia coli) resulted in an increase in
inflammatory cytokines, including TNF-alpha, IL-1β, IL-6, and
IL-10. When placentas were pre-treated with progesterone
(4-pregnene-3, 20-dione), significant blunting in the secretion
of these pro-inflammatory cytokines was appreciated.22
Results from specific in vitro evaluation of 17-OHPC with
regards to mechanisms of action have been less consistent.
In one study, pregnant mice were pre-treated with either
vaginal progesterone or 17-OHPC before exposure to lipopo-
lysaccharide to induce inflammation-mediated preterm birth.
Researchers found that vaginal progesterone, but not 17-
OHPC, had significant anti-inflammatory effects at the level
of the cervix, as it increased the proportion of decidual CD5þ
regulatory T-cells, decreased the proportion of CD8þ CD25þ
Foxp3þ T-cells and macrophages, and reduced the proportion
of myometrial interferon-gamma neutrophils and MMP-9
positive neutrophils and monocytes.23 In another murine
study focusing on expression of uterine contraction-associ-
ated proteins (connexin-43, oxytocin receptor, and cycloox-
ygenase-2) and miRNA, 17-OHPC did not alter levels of the
studied contractile proteins or alter pathways involved with
cervical remodeling.24 In contrast, Elovitz and colleagues
evaluated the effect of pretreating mice with various both
medroxyprogesterone acetate and 17-OHPC prior to exposing
them to intrauterine lipopolysaccharide; though medroxy-
progesterone acetate was more effective, both formulations
resulted in the prevention of preterm birth and resulted in
the delivery of live pups at term.25
General properties and pharmcokinetic characteristics of
17-OHPC
17-OHPC differs from naturally occurring 17-alpha hydroxy-
progesterone by addition of a caproate group, which serves to
prolong its half-life. 17-OHPC is synthesized by the acetyla-
tion of 17-alpha hydroxyprogesterone with caproic acid in the
presence of toluene sulfonic acid.26 It is lipophilic and highly
protein bound, and is highly stable in the presence of strong
acid, high temperatures, and light.27 The most common dose
is 250 mg, administered by intramuscular injection every 7
days. However, this dosing regimen is empiric, and wide
variation in 17-OHPC concentrations is observed between
individuals in pharmacokinetic studies.28,29
17-OHPC is metabolized by human hepatocytes and liver
microsomes by the highly polymorphic cytochrome P450
(CYP) enzyme system, primarily by CYP3A5. Considerable
inter-individual variability in the CYP3A5 gene has been
reported, which may result in variation in the catalytic
activity of the enzyme by as much as 90-fold.30 After admin-
istration, peak concentrations are reached in 1–2 days, and
the half-life of 17-OHPC is 10–16 days.28,29 This half-life is
variable between individuals, with notable differences seen
with variance in maternal body mass index and race, and is
shorter in twin gestations.28,29,31 In general, non-Hispanic
black women have higher clearance and therefore lower
concentrations of 17-OHPC compared to non-Hispanic white
women. These differences by race and ethnicity are theorized
to be at least partly attributable to known genetic differences
in the CYP3A enzyme system, as the CYP3A5 is the predom-
inant CYP3A enzyme in 50% of non-Hispanic black women
but only 30% of non-Hispanic white women.32 17-OHPCcrosses the placenta and has been detected in cord blood
plasma as long as 44 days after the last maternal injection.29
Because the volume of progesterone produced by the
placenta is large, supplementation with additional natural
or synthetic progesterone would not be expected to raise the
overall serum levels of progesterone significantly. Some
critics, therefore, doubt the ability of additional supplemen-
tation to locally impact the myometrium or affect clinical
outcomes. However, unlike other species where a sudden
change in gene signaling occurs at term, human pregnancy is
characterized by a more gradual change in progesterone gene
signaling, contributing to the functional progesterone with-
drawal as described above.
The relationship between 17-OHPC level and clinical out-
comes has been evaluated in an attempt to explain part of the
variation in clinical outcomes that is observed among women
on 17-OHPC. Caritis et al. evaluated the plasma concentra-
tions of 17-OHPC of 315 women receiving 17-OHPC for
recurrent preterm birth prevention to determine the relation-
ship between 17-OHPC concentration and clinical efficacy.
Blood samples were obtained at a median 27 weeks' gestation
after a median of 9 injections. Women with the lowest
quartiles of 17-OHPC concentrations (o8.2 ng/mL) were sig-
nificantly more likely to experience recurrent preterm birth
(46.3% for lowest quartile vs. 29.2% for women in other 3
quartiles).33 These findings are in contrast to a large prospec-
tive observational cohort of primarily Hispanic women where
maternal 17-OHPC plasma levels were obtained at 24 and
32 weeks; and there were no observed differences in median
17-OHPC levels were observed when women who delivered
≤35 weeks' gestation were compared with those who
delivered 435 weeks' gestation.34 Though it is possible there
is a critical “minimum concentration” required to achieve
17-OHPC efficacy, there are currently insufficient data to
support routine clinical use of 17-OHPC levels or individu-
alized 17-OHPC dose adjustments, though these remain
active areas of research.Clinical Use of 17-OHPC
17-OHPC is approved for the prevention of recurrent preterm
birth among women with a prior singleton spontaneous
preterm birth, 20–36 weeks' gestation. 17-OHPC has been
commercially available since 2011, and is recommended for
use by the FDA instead of compounded drug alternatives,
except when there is a specific medical need (e.g., allergy)
that cannot be met by the approved drug. Recently, recogniz-
ing the somewhat arbitrary nature of the lower gestational
age limit cutoff, some experts have recommend extending
the use of 17-OHPC and also offering it to women with a prior
spontaneous preterm birth between 16 and 20 weeks' ges-
tation, as women with such a history have a particularly high
risk of recurrent preterm birth and may also benefit, though
no high-quality data are available to support this recommen-
dation.11,35,36 Offering 17-OHPC women with a previous pre-
term birth is the consensus recommendation of the Society
for Maternal–Fetal Medicine and the American Congress of
Obstetricians and Gynecologists.37,38 Current dosing recom-
mendations are 250 mg intramuscular weekly, beginning at
16–20 weeks' gestation and continued through 36 weeks'
gestation. Some studies suggest that earlier initiation (e.g.,
closer to 16 weeks) may be associated with improved out-
comes, though this hypothesis has not been directly tested.39
Benefit can be seen if 17-OHPC is initiated as late as 28 weeks'
gestation. Early discontinuation and poor compliance with
weekly injections is associated with treatment failure and
increased rates of recurrent preterm birth, though these
analyses should be interpreted with caution due to
confounding.
17-OHPC is classified by the US FDA as Pregnancy Category B
(no known adverse effects). Limited longer term follow-up data
do not suggest any adverse long-term effects; 194 children
exposed to 17-OHPC in the NICHD Meis trial were evaluated at
a mean of 48 months of age and had similar health outcomes
and neurodevelopment to 84 children in the placebo group.40
No consistent adverse maternal effects to 17-OHPC have
been identified; the most common side effects are local
injection site reactions including bruising, swelling, and skin
irritation. However, progestogens are known to alter the
physiology of glucose transport into the cell and also may
impact the release of insulin.41 The extent to which these
physiologic changes in glucose metabolism also occur in
response to 17-OHPC, and whether this is clinically mean-
ingful (such as the diagnosis of gestational diabetes or
glucose intolerance) remains controversial. Studies evaluat-
ing the relationship between 17-OHPC exposure and gesta-
tional diabetes are varied, as the incidence is highly
dependent on the population studied and other risk factors
(e.g., obesity and race). In a secondary analysis that included
2 primary studies and women with singleton and twin
gestations randomized to 17-OHPC vs. placebo, rates of gesta-
tional diabetes not increased among women exposed to
17-OHPC compared to those women unexposed (5.8% vs.
4.7%, p ¼ 0.64 for singletons and 7.4% vs. 7.6%, p ¼ 0.94).42
In contrast, in 2014 Egerman and colleagues performed a
retrospective study of 491 obese women (prepregnancy body
mass index ≥ 30 kg/m2) who received 17-OHPC (exposed
cases) and 408 obese women who were undergoing daily
uterine activity monitoring (unexposed controls), andTable – Factors associated with variable pregnancy outcomes a
caproate.
Factor type Characteristic




Previous pregnancy delivered following spontaneous
labor (vs. preterm premature rupture of membrane
Prior preterm birth o34 weeks62
Current
pregnancy
Maternal body mass index63,64
Placental abruption or significant vaginal bleeding44,4
Gonorrhea or chlamydia in the current pregnancy44
Male fetus44
Penultimate delivery was preterm44,45
Maternal
genetics
Nitric oxide signal transduction, cell adhesion, cell
communication, signal transduction49reported a higher incidence of gestational diabetes among
women exposed to 17-OHPC (13.8% vs. 9.6%, p ¼ 0.048).43 A
recent report from a prospectively collected cohort of 430
primarly Hispanic women with a previous preterm birth
treated with 17-OHPC found 13.4% developed gestational
diabetes, significantly higher than the 8% rate of gestational
diabetes in a historic cohort.34 Therefore, though neither a
direct relationship nor causality between 17-OHPC has not
been established, clinicians caring for women who are
exposed to 17-OHPC should remain vigilant and perform
early screening for gestational diabetes if there symptoms
of glucose intolerance develop.
Factors influencing successful treatment with 17-OHPC
Unfortunately, not all women have successful term deliveries
when treated with 17-OHPC. Identification of those individu-
als most likely to experience recurrent preterm birth despite
17-OHPC may aid clinical decision making with regards to
intensity of prenatal care, timing of administration of ante-
natal corticosteroids, or enrollment in prospective research to
investigate new therapeutic options. It is possible that risk
factors from the prior pregnancy, or the underlying etiology
behind the initial preterm birth influences the likelihood of
recurrent preterm birth in the 17-OHPC treated pregnancy.
Gonzalez-Quintero and colleagues evaluated 2123 women
with one prior spontaneous preterm birth and classified the
prior premature delivery as either due to “preterm labor”or
“preterm premature rupture of membranes.” They found that
among this group of 17-OHPC treated women, those with a
history of a prior preterm birth due to preterm labor had
higher rates of recurrent spontaneous preterm birth o37
weeks (29.7% vs. 22.9%, p ¼ 0.004), o35 weeks (14.0% vs.
9.1%, p ¼ 0.004), and o32 weeks (5.9% vs. 3.3%, p ¼ 0.024).44
These findings were confirmed in a separate cohort of 1183
singletons, where delivery due to spontaneous preterm labor
in the previous pregnancy was associated with recurrent
preterm birth (OR ¼ 1.66, 95% CI: 1.16–2.37).45
Limited studies have investigated factors associated with
recurrent preterm birth in the current gestation. Twomong women treated with 17-alpha hydroxyprogesterone
Association
45 Higher rate of recurrent preterm birth
preterm
s)44,45
Higher rate of recurrent preterm birth
Improved prolongation of pregnancy compared
to women with later previous preterm births
Higher rate of recurrent preterm birth with
higher maternal body mass index
5 Higher rate of recurrent preterm birth
Pathway over-represented among women with
recurrent preterm birth on 17-OHPC49
separate studies suggest that the presence of vaginal bleeding
and a penultimate preterm birth are associated with an
increased risk of recurrent preterm birth despite 17-OHPC
therapy.46,47 Other clinical factors in the current pregnancy
may also influence outcomes (Table). Finally, maternal and
fetal genetics has also been evaluated as potentially influenc-
ing pregnancy outcomes and risk for recurrent preterm birth.
This area of research, pharmacogenomics, investigates the
association between certain genomic and epigenomic
changes and response to 17-OHPC therapy for prematurity
prevention. Though studies are small, some suggest that both
maternal and fetal genetics may impact pregnancy outcomes
among women treated with 17-OHPC. Differences in broad
pathways including molecular signaling, cell adhesion, and
receptor activity, as well as more specific genetic targets such
as the progesterone receptor and nitric oxide synthase have
been implicated (Table).48,49
Real world efficacy and impact of 17-OHPC
Multiple studies have evaluated the efficacy of 17-OHPC in
the prevention of preterm birth. Mason et al. evaluated the
effects of providing 17-OHPC to a high-risk, Medicaid popu-
lation over a 5-year period, and found a reduction in deliv-
eries o35 weeks (41.7% in control group and 26.4% in 17-
OHPC group) and in the rate of NICU admission (45.0% in
control group and 33.7% in 17-OHPC group) when 17-OHPC
was initiated by 28 weeks' gestation. In 2012, Sibai et al.
reported preterm birth rates less than 37 weeks' gestation
were similar (34.4% vs. 36.3%) in a high-risk cohort of 5393
women receiving 17-OHPC through a home nurse adminis-
tration care management program to the original NICHD Meis
study. They also found no significant differences in adverse
outcomes, suggesting that real world implementation in a
home setting was safe and effective.50 Most recently, Nelson
et al.34 published results from a prospective cohort of 430
women with prior births o35 weeks' gestation who received
locally compounded 17-OHPC in the current pregnancy.
Women treated with 17-OHPC (January 2012–March 2016) at
a single center were compared to a historic cohort (1998–
2001), and evaluated for recurrence of PTB o35 weeks'
gestation. The study reported a PTB recurrence rate o35
weeks' gestation of 25%, similar to the rate of 23% in the
historic cohort (p ¼ 0.45), and concluded that 17-OHPC is
ineffective in reducing the rate of recurrent prematurity.
Moreover, the authors raised concern regarding the increase
in the incidence of gestational diabetes in women treated
with 17-OHPC, reporting a 13.4% incidence among women
exposed to 17-OHPC compared with 8% in the historic cohort
(p ¼ 0.001). Unfortunately, it is difficult to discern the validity
of these findings due the inherent errors in using a historic
cohort for comparison.
It is difficult to evaluate the impact of 17-OHPC on rates of
prematurity, as the addition of this intervention did not occur
in isolation. Practice changes in obstetric care in the 2000s
and early 2010s, including transvaginal cervical length
screening, use of cervical cerclage, and vaginal progesterone
to treat women with a shortened mid-trimester cervical
length—along with 17-OHPC use—are estimated to have
contributed the recent modest reductions in preterm birthin the United States. It is estimated that 17-OHPC use is
directly responsible for the prevention of approximately
10,000 preterm births in the United States each year.51–53
Use of 17-OHPC in other high-risk groups to prevent
prematurity
Progesterone as a tocolytic or adjunct tocolytic
Limited investigations have evaluated the efficacy of proges-
togens as acute tocolytics or adjuncts to acute tocolysis. One
of the largest studies of progesterone as an acute tocolytic
was a multi-center study in Europe. Investigators randomized
385 women at 24–33.9 weeks' gestation with singleton preg-
nancies and acute preterm labor within 48 h of starting acute
tocolysis to receive either 200 mg of vaginal progesterone or
placebo. Progesterone use was not associated with reduction
in the primary outcome of preterm birth prior to 37 weeks of
gestation (RR ¼ 1.2, 95% CI: 0.93–1.5), nor with any of the other
pre-specified obstetric or neonatal outcomes.54 Also in 2015, a
meta-analysis was published and included 5 randomized
controlled trials (441 singleton pregnancies) with arrested
preterm labor found that women who received vaginal
progesterone had improved outcomes, including significantly
longer latency (mean improvement ¼ 13.8 days), later gesta-
tional age at delivery (mean improvement ¼ 1.3 weeks), lower
rates of recurrent preterm labor (24% vs. 46%; RR ¼ 0.51, 95%
CI: 0.31–0.84), and lower rates of neonatal sepsis (2% vs. 7%;
RR ¼ 0.34, 95% CI: 0.12–0.98).55
A second meta-analysis in 2015 evaluated the role of
17-OHPC as a maintenance tocolytic, and also found prolon-
gation in latency between the initial episode of preterm labor
and eventual delivery with progesterone supplementation
compared with placebo (mean improvement ¼ 8.4 days),
and later gestational age at delivery compared with placebo
(mean improvement ¼ 2.3 weeks), though rates of preterm
birth less than 37 and less than 34 weeks were similar
between groups (42% vs. 51%; RR ¼ 0.78, 95% CI: 0.50–1.22).56
Unfortunately, the trials included in both of these meta-
analyses were of generally poor quality; for example, many
were unblinded, limiting the conclusions that can be drawn
from these data. Additional rigorous randomized controlled
trials are needed to evaluate the efficacy of progestogens as
maintenance tocolytics. At the current time, there is insuffi-
cient evidence to support routine use of either vaginal or
intramuscular progesterone in the setting of active or
arrested preterm labor.
17-OHPC for prevention of preterm birth in other high-risk
populations
Given the success of 17-OHPC in prematurity prevention
among women with a prior preterm birth, use of this
intervention has also been evaluated in other high-risk
populations, including multiple gestations and nulliparous
women with a short cervix in the mid-trimester. In a large
randomized controlled trial conducted by the NICHD Mater-
nal Fetal Medicine Units Network, 691 women with twin
pregnancies were randomized to receive either weekly 17-
OHPC injections or placebo starting at 16–20 weeks' gestation
until 36 weeks' gestation or delivery. However, 17-OHPC did
not decrease the rate of preterm birth o35 weeks' gestation
(RR ¼ 1.1, 95% CI: 0.9–1.3) or the composite neonatal adverse
outcome (RR ¼ 1.1, 95% CI: 0.9–1.5) in this population.57 In an
open label trial of 165 women with twin gestations evaluating
twice weekly injections of 500 mg of 17-OHPC, a higher rate of
preterm birth o32 weeks was seen among women exposed
to 17-OHPC (29% vs. 12%, p ¼ 0.007), though rates of preterm
birth o34 and o37 weeks were not different between
groups.58 Similar negative findings were appreciated in a
randomized trial of 17-OHPC in 134 women with triplets
(RR ¼ 1.0, 95% CI: 0.9–1.1).59 Studies evaluating the efficacy
of 17-OHPC in the prevention of prematurity among women
with a short cervical length have also been negative.60,61 The
bulk of the evidence from these studies in women at high risk
for preterm birth for other indications does not support
supplementation with 17-OHPC at the current time.Conclusions
Though much progress has been made, rates of recurrent
preterm birth remain unacceptably high in the United States.
Additional research is urgently needed to further elucidate
both the underlying pathophysiology behind recurrent pre-
term birth despite 17-OHPC therapy and the clinical factors
that influence outcomes. Additional refinements in 17-OHPC
dosing regimens, consideration of adjunct therapies, and
potentially evaluation of maternal and/or fetal genetics may
help lower rates of recurrent preterm birth in the future.
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